Doxorubicin-loaded cell-derived nanovesicles: An alternative targeted approach for anti-tumor therapy

International Journal of Nanomedicine

Volumn 12, Issue , 2017, Pages 2759-2767

  Goh, Wei Jiang ^a,b   Lee, Choon Keong ^b   Zou, Shui ^b   Woon, Esther C Y ^b   Czarny, Bertrand ^b,c   Pastorin, Giorgia ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Antitumor strategies; Antitumor therapy; Biomimetic; Bionanotechnology; Cell targeting; Cell derived nanovesicles; Doxorubicin; Extracellular vesicles

Indexed keywords

DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC; NANOMATERIAL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL DIFFERENTIATION; CELL FUNCTION; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; DRUG UPTAKE; HEK293 CELL LINE; HELA CELL LINE; HUMAN; MEMBRANE MICROPARTICLE; ANIMAL; CHEMISTRY; COCULTURE; MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HEK293 CELLS; HELA CELLS; HUMANS; MICE; NANOSTRUCTURES;

EID: 85017373016     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S131786     Document Type: Article

References (17)

1. Estanqueiro M, Amaral MH, Conceição J, Sousa Lobo JM. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B Biointerfaces. 2015;126:631–648.
2. Sajid MI, Jamshaid U, Jamshaid T, Zafar N, Fessi H, Elaissari A. Carbon nanotubes from synthesis to in vivo biomedical applications. Inter J Pharm. 2016;501(1–2):278–299.
3. Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.
4. Zhu Y, Liao L. Applications of nanoparticles for anticancer drug delivery: a review. J Nanosci Nanotechnol. 2015;15(7):4753–4773.
5. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3): 136–151.
6. Szebeni J, Storm G. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs. Biochem Biophys Res Commun. 2015;468(3):490–497.
7. Fais S, Logozzi M, Lugini L. Exosomes: the ideal nanovectors for biodelivery. Biol Chem. 2013;394(1):1–15.
8. Marcus ME, Leonard JN. FedExosomes: engineering therapeutic biological nanoparticles that truly deliver. Pharmaceuticals (Basel). 2013;6(5):659–680.
9. Jang SC, Kim OY, Yoon CM, et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano. 2013;7(9):7698–7710.
10. Jo W, Kim J, Yoon J, Jeong D, et al. Large-scale generation of cellderived nanovesicles. Nanoscale. 2014;6:12056–12064.
11. Roth JC, Curiel DT, Pereboeva L. Cell vehicle targeting strategies. Gene Ther. 2008;15(10):716–729.
12. Mahajan-Thakur S, Sostmann BD, Fender AC, et al. Sphingosine-1phosphate induces thrombin receptor PAR-4 expression to enhance cell migration and COX-2 formation in human monocytes. J Leukoc Biol. 2014;96(4):611–618.
13. Tian Y, Li S, Song J, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35(7):2383–2390.
14. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25.
15. Haney MJ, Klyachko NL, Zhao Y, et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Control Release. 2015;207: 18–30.
16. Fülöp Z, Gref R, Loftsson T. A permeation method for detection of self-aggregation of doxorubicin in aqueous environment. Int J Pharm. 2013;454(1):559–561.
17. Arora HC, Jensen MP, Yuan Y, et al. Nanocarriers enhance doxorubicin uptake in drug-resistant ovarian cancer cells. Cancer Res. 2012; 72(3):769–778.